Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announces Rybelsus package-insert revision adding cardiovascular trial results

添付文書改訂相談に基づく添付文書改訂(医薬品)を掲載しました

Published: 2026-11-13 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-11-14

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-11-13, the Pharmaceuticals and Medical Devices Agency (PMDA) listed a consultation-based package-insert revision for Novo Nordisk Pharma Ltd.'s Rybelsus tablets, 3 mg, 7 mg and 14 mg (semaglutide, recombinant). The supporting document dated 2026-07-15 describes adding results from trial EX9924-4473 as new section 17.1.7 under Clinical Results; it lists the indication as type 2 diabetes. The placebo-controlled, double-blind international Phase III trial enrolled 9,650 patients with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both. The excerpt reports superiority over placebo for time to the first major cardiovascular event, with a hazard ratio of 0.86 (95% confidence interval: 0.77–0.96). This is a package-insert revision announcement, not an announcement of a new indication; no implementation deadline is stated in the excerpts.

Business Impact

The revision may affect Novo Nordisk Pharma Ltd.'s product-information materials for the three listed Rybelsus strengths. Healthcare professionals using those products may find additional cardiovascular outcomes evidence in the revised Clinical Results section.

Recommended Action

A review could compare new section 17.1.7 with existing Rybelsus product-information materials, checking the trial population and cardiovascular endpoint wording without treating the added results as an expanded indication.